Viking Therapeutics: Can This Weight Loss Stock Double?

Viking Therapeutics (VKTX) is a clinical-stage biotech developing VK2735, a promising weight loss drug that combines GLP-1 and GIP mechanisms. The company recently reported positive top-line results from a maintenance study where patients received an initial 19-week subcutaneous dose followed by weekly, biweekly, or monthly maintenance dosing. These results drove a surge in the stock price.

Following the positive data, Viking raised $500 million through a stock and convertible senior note offering to fund further pipeline development. This capital raise strengthens the company's balance sheet as it prepares for late-stage trials.

The next key catalyst is the second part of the maintenance study, which will test an oral formulation of VK2735 as a maintenance dose. This is crucial because the oral version previously showed tolerability issues in a phase 2 trial. If the oral maintenance data is positive, it would validate Viking's dual-formulation strategy—using injectables for rapid weight loss and orals for convenient maintenance.

Viking plans to initiate a phase 3 trial of the oral formulation in 2026. The company's CEO, Brian Lian, has emphasized that even a small share of the massive obesity market could lead to a successful franchise. Morgan Stanley estimates the global obesity drug market could exceed $77 billion by 2030, and analysts project Viking could generate $1.2 billion in revenue if it captures just 1.4% of that market.

With a market cap of around $4 billion, Viking's stock has significant upside potential if VK2735 succeeds. However, as a clinical-stage biotech, the stock is highly speculative and subject to binary outcomes from trial results.

The obesity drug market is one of the most lucrative opportunities in healthcare, with billions in potential revenue. Viking Therapeutics is positioning itself as a differentiated player with a dual-formulation strategy that could offer better convenience and tolerability than existing treatments. If successful, VK2735 could capture a meaningful share of this market, driving substantial revenue and stock appreciation.

For investors, Viking represents a high-risk, high-reward opportunity. Positive clinical data could send the stock soaring, while any safety or efficacy concerns could cause a sharp decline. The recent $500 million raise reduces near-term financing risk but also dilutes existing shareholders.

Competition is fierce, with established players like Eli Lilly (LLY) and Novo Nordisk dominating the space. However, Viking's innovative approach and potential for oral maintenance could carve out a niche. The market's reaction to Viking's data suggests that investors see it as a credible challenger, though Lilly's stock barely moved, indicating limited perceived threat to the leader.

Looking ahead, the oral maintenance data will be a major catalyst. Success there could pave the way for a phase 3 program and partnership opportunities. Conversely, poor tolerability could delay or derail the oral program, leaving Viking reliant on injectables in a crowded market. Given the binary nature of biotech investing, position sizing and risk tolerance are critical.